Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. As a result of the transaction, Amira has become a wholly-owned subsidiary of Bristol-Myers Squibb.

The acquisition of Amira Pharmaceuticals’ fibrosis program, including the lead asset AM152, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist which has completed Phase I clinical studies and is now poised for Phase IIa proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic Sclerosis (SSc), or scleroderma, marks Bristol-Myers Squibb’s entrance into fibrotic diseases, an area of high unmet medical need which is complementary to its current therapeutic areas of focus. Bristol-Myers Squibb also has obtained Amira’s preclinical autotaxin program, which may be useful in the treatment of neuropathic pain and cancer metastases.

The transaction was originally announced on July 21, 2011, and has met all customary regulatory approval obligations.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, relating to the acquisition of Amira Pharmaceuticals, Inc. by Bristol-Myers Squibb Company, and the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the compounds described in this release will move from early stage development into full product development, that clinical trials of these compounds will support a regulatory filing, or that these compounds will receive regulatory approval or become commercially successful products. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.



CONTACT:

Bristol-Myers Squibb Company
Media
Jennifer Mauer, 609-252-6579
[email protected]
or
Investors
John Elicker, 609-252-4611
[email protected]
or
Teri Loxam, 609-252-3368
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.

The IPO window is still wide open for biotech, and French Big Pharma-partnered Innate is looking to jump right on through.

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.